Cerebrolysin is a low molecular weight, porcine-derived peptide preparation with free amino acids that has a variety of clinical applications due to its neuroprotective and neurotrophic properties. It is used as a neurotrophic agent for the treatment of ischemic stroke, brain trauma, and Alzheimer’s Disease. Cerebrolysin also known as  FPE 1070  consists of low-molecular peptides and possesses neuroprotective and neurotrophic repair properties. The active fragment of cerebrolysin is made of low molecular proteins that can penetrate the blood-brain (or blood-SCF) barrier.  Cerebrolysin has been proven to have neurotrophic action similar to nerve growth factors causing peripheral and central neuronal stimulation. It improves efficiency within the brain’s metabolism and improves cellular peptide synthesis. The neuroprotective properties of Cerebrolysin help to protect brain cells from lactic acid,  reduce the formation of free radicals and to decrease the neurotoxicity of certain amino acids.*

*Results may vary

Neurotrophic factors are molecules that are responsible for growing, maintaining and repairing neurons. They also have neuroprotective properties that strengthen neural pathways and the integrity of the neurons themselves. They are also responsible for promoting synaptic plasticity, which is a way the brain strengthens certain neural pathways. In situations where the brain needs to utilize neurotrophic factors to repair damaged neurons, such as in the case of neurological disease, Cerebrolysin can be administered to act as an analog to endogenous neurotrophic factors. Studies have shown that the use of Cerebrolysin as treatment of neurodegenerative disease has often proved effective as a means of symptomatic treatment as well as pathological suppression in both the short and long term. Additionally, due to its neuroprotective properties, Cerebrolysin has been shown to have the preventative potential for individuals who have a genetic predisposition to developing Alzheimer’s disease. Cerebrolysin’s neurotrophic effects may reduce the neurodegenerative pathology in Alzheimer’s disease (AD). It decreases amyloid burden but the mechanisms involved are not understood. Cerebrolysin might reduce amyloid deposition by regulating amyloid (Ab) degradation or by modulating APP expression, maturation, or processing.*

Call 678-443-4000 today!